retatrutide gip glp-1 glucagon receptor agonist Retatrutide, a GIP, and agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA Eli Lilly: GLP-1R/GCGR/GIPR Triagonist Reduces
Description
Efficacy studies have demonstrated this additive effect with metformin, sulfonylureas, and thiazolidinediones given in combination with saxagliptin and linagliptin

Noronha JC, Braunschweig CL, Gracey E, et al

J., Parkes, D., Feigh, M., Suschak, J

Analysts project high double-digit compound annual growth rates

Immunol Cell Biol (2008) 86(8):6508
